SecBot SecBot
DEF 14A ·Filed Nov 12, 2026

XCUR

EXICURE, INC.
BEARISH
Impact 6/10
Horizonweeks Processed4d 9h ago SEC0001193125-26-457986
Definitive proxy statement
Actionable Insight ▼ Bearish

The financing terms (75% of Nasdaq Minimum Price, 3 warrants per share) are highly dilutive. Monitor the actual pricing and size of any placement after the Dec 2 meeting. The 33.95% holder HiTron's support is likely needed for the share increase proposal which requires a majority of outstanding shares.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.06
T+0 close · Nov 12, 2026 · via day close
Latest settled
+1.89%
T+1 · $1.08
Vs SPY
+2.25%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.06entry
  2. T+1 · 4d ago +1.89%α +2.25% · $1.08
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Exicure is seeking shareholder approval for a dilutive financing of up to $10M, a new equity plan covering 981,899 shares (15% of outstanding), and a doubling of authorized shares to 400M. The company has a $7M market cap, a net loss of $9.7M in 2024, and has experienced complete management turnover. The activist stake by Exicure HiTron (33.95% owner) adds context but the proxy itself shows no contested items.

Key Facts

  • Proposal 3 authorizes up to $10M in private placement with units of 1 share + 3 warrants, at the lesser of $1.30 or 75% of Nasdaq Minimum Price
  • Proposal 4 creates a 2026 omnibus plan reserving 981,899 shares (15% of outstanding), with automatic annual increases
  • Proposal 5 doubles authorized common shares from 200M to 400M
  • 6,545,995 shares outstanding as of record date; $7M market cap
  • 2024 net loss of $9.7M; no revenue disclosed
  • Exicure HiTron owns 33.95% of shares; filed SC 13D/A in July 2026
  • All named executive officers (CEO, CFO) resigned in early 2026; current CEO Jung Soo Kim appointed Feb 2026
  • No Say-on-Pay vote or shareholder proposals on the ballot

Financial Impact

Up to $10M gross proceeds from financing; potential dilution of up to 4x units sold (share + 3 warrants); authorized share count doubling from 200M to 400M

dilutionauthorized sharesequity compensation

Risk Factors

  • Massive dilution from up to $10M financing with 3:1 warrant coverage
  • Authorized share increase could enable further dilutive issuances without additional votes
  • Company has no revenue and continues to burn cash with $9.7M net loss
  • Complete management and board turnover suggests operational instability

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001193125-26-457986
Document: 0001193125-26-457986-index-headers.html0001193125-26-457986
Document: 0001193125-26-457986-index.html0001193125-26-457986
Document: 0001193125-26-457986.txt0001193125-26-457986

US Market Status

Market Closed · Opens Wed (9h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026